Mechanisms of platelet activation in recovered COVID-19 patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025217

Enrollment

Registered

2021-04-29

Start date

2021-04-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Group 1: Patients after recovery from Covid-19 infection are investigated using a study specific questionnaire and a blood sample. Group 2: Individuals (matched for age and sex) who have never been in

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. able to provide informed consent 2. Individuals who have been infected and had a mild COVID-19 disease (reconvalescents). These individuals had typical symptoms for at least 5 days but have never been treated in the hospital. These individuals are fully receovered at study inclusion. 3. Individuals who have been infected and had a severe COVID-19 disease (reconvalescents). These individuals were hospitalized for COVID-19 disease. These individuals are fully receovered at study inclusion. 4. Healthy volunteers never infected with SARS-CoV-2 (control group).

Exclusion criteria

Exclusion criteria: 1. Intake (regular or acute within 7 days of blood sample) of drugs interfering with platelet function (e.g. acetyl salicylic acid, ibuprofen, antidepressants of SSRI and SSNRI class). 2. platelet dysfunction or thrombocytopenia 3. pregancy and lactation period

Design outcomes

Primary

Measure	Time frame
Difference in platelet activation measured by light transmission aggregation	—

Secondary

Measure	Time frame
1. Formation of thrombin by Calibrated Automated Thrombogram 2. Determination of specific markers of platelet activation (e.g. CD62, PAC1) 3. Determination of platelet surface markers Bestimmung von (e.g. CD62, CD63, GPVI, HLA) 4. Influence of MRP4 inhibition with Ceefourin-1 on pletelet function 5. MRP4 expression and factors of S1P metabolism in pletelets 6. S1P concentrationen and thromboxan B2 concentration in plasma 7. pletelet count 8. SARS-CoV-2 antibodies in serum	—

Measure

Time frame

1. Formation of thrombin by Calibrated Automated Thrombogram 2. Determination of specific markers of platelet activation (e.g. CD62, PAC1) 3. Determination of platelet surface markers Bestimmung von (e.g. CD62, CD63, GPVI, HLA) 4. Influence of MRP4 inhibition with Ceefourin-1 on pletelet function 5. MRP4 expression and factors of S1P metabolism in pletelets 6. S1P concentrationen and thromboxan B2 concentration in plasma 7. pletelet count 8. SARS-CoV-2 antibodies in serum

—

Countries

Germany

Contacts

Public ContactStefan Engeli

Institut für Pharmakologie, Universitätsmedizin Greifswald

stefan.engeli@med.uni-greifswald.de+49 3834 86 5633

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026